Antiglaucoma Drug GLC756 and Its Effect on Cellular cAMP and Tumor Necrosis Factor α Release In Vitro of Activated Human Monocytic Leukemia Cells
スポンサーリンク
概要
- 論文の詳細を見る
- 2009-03-01
著者
-
Markstein Rudolf
Novartis Pharma Ag Basel Che
-
Markstein Rudolf
Novartis Pharma Ag Department Of Toxicology & Pathology
-
Roman Danielle
Novartis Pharma Ag Department Of Toxicology & Pathology
-
Laengle Ulrich
Novartis Pharma Ag Department Of Toxicology & Pathology
-
CAZAUBON Cencile
Novartis Pharma AG, Department of Toxicology & Pathology
-
Cazaubon Cencile
Novartis Pharma Ag Department Of Toxicology & Pathology
-
Cazaubon Cecile
Novartis Pharma AG, Department of Toxicology & Pathology
関連論文
- Antiglaucoma Drug GLC756 and Its Effect on Cellular cAMP and Tumor Necrosis Factor α Release In Vitro of Activated Human Monocytic Leukemia Cells
- TOPICAL SDZ GLC-756, A NOVEL DOPAMINE D-1 ANTAGONIST AND D-2 AGONIST, LOWERS INTRAOCULAR PRESSURE IN CONSCIOUS RABBITS